S Oberbeck,A Schrader,K Warner,D Jungherz,G Crispatzu,J von Jan,M Chmielewski,A Ianevski,H H Diebner,P Mayer,A Kondo Ados,L Wahnschaffe,T Braun,T A Müller,P Wagle,A Bouska,T Neumann,S Pützer,L Varghese,N Pflug,M Thelen,J Makalowski,N Riet,H J M Göx,G Rappl,J Altmüller,M Kotrová,T Persigehl,G Hopfinger,M L Hansmann,H Schlößer,S Stilgenbauer,J Dürig,D Mougiakakos,M von Bergwelt-Baildon,I Roeder,S Hartmann,M Hallek,R Moriggl,M Brüggemann,T Aittokallio,J Iqbal,S Newrzela,H Abken,M Herling

Abstract:T-cell prolymphocytic leukemia (T-PLL) is a poor-prognostic neoplasm. Differentiation stage and immune-effector functions of the underlying tumor cell are insufficiently characterized. Constitutive activation of the T-cell leukemia 1A (TCL1A) oncogene distinguishes the (pre)leukemic cell from regular postthymic T cells. We assessed activation-response patterns of the T-PLL lymphocyte and interrogated the modulatory impact by TCL1A. Immunophenotypic and gene expression profiles revealed a unique spectrum of memory-type differentiation of T-PLL with predominant central-memory stages and frequent noncanonical patterns. Virtually all T-PLL expressed a T-cell receptor (TCR) and/or CD28-coreceptor without overrepresentation of specific TCR clonotypes. The highly activated leukemic cells also revealed losses of negative-regulatory TCR coreceptors (eg, CTLA4). TCR stimulation of T-PLL cells evoked higher-than-normal cell-cycle transition and profiles of cytokine release that resembled those of normal memory T cells. More activated phenotypes and higher TCL1A correlated with inferior clinical outcomes. TCL1A was linked to the marked resistance of T-PLL to activation- and FAS-induced cell death. Enforced TCL1A enhanced phospho-activation of TCR kinases, second-messenger generation, and JAK/STAT or NFAT transcriptional responses. This reduced the input thresholds for IL-2 secretion in a sensitizer-like fashion. Mice of TCL1A-initiated protracted T-PLL development resembled such features. When equipped with epitope-defined TCRs or chimeric antigen receptors, these Lckpr-hTCL1Atg T cells gained a leukemogenic growth advantage in scenarios of receptor stimulation. Overall, we propose a model of T-PLL pathogenesis in which TCL1A enhances TCR signals and drives the accumulation of death-resistant memory-type cells that use amplified low-level stimulatory input, and whose loss of negative coregulators additionally maintains their activated state. Treatment rationales are provided by combined interception in TCR and survival signaling.

Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins

The protooncogene TCL1 is an Akt kinase coactivator

The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways

Proto-oncogene TCL1: more than just a coactivator for Akt

Crystal structures of Tcl1 family oncoproteins and their conserved surface features

Role of Phosphatidylinositol 3-Kinase and Specific Protein Kinase B Isoforms in the Suppression of Apoptosis Mediated by the Abelson Protein-tyrosine Kinase

The TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB

High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia

T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways

T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia

AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1

Structural transitions in TCTP tumor protein upon binding to the anti-apoptotic protein family member Mcl-1

The TCL1 oncoprotein binds the RNase PH domains of the PNPase exoribonuclease without affecting its RNA degrading activity

The TCL1 family of oncoproteins: co-activators of transformation

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

Protein Kinase C Activation Inhibits Tyrosine Phosphorylation Of Cbl And Its Recruitment Of Src Homology 2 Domain-Containing Proteins

TCL1: a new drug target in lymphoid and germ-cell malignancies?

Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling

PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway